Related Experiment Video
Updated: Nov 26, 2025

Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Neonatal hyperbilirubinemia management: Clinical assessment of bilirubin production
Lizhong Du1, Xiaolu Ma1, Xiaoxia Shen1
1Department of Neonatology, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Child Health, China.
Insights
Elevated bilirubin in newborns often signals hemolysis. A new point-of-care device measuring end-tidal carbon monoxide (ETCOc) effectively identifies hemolysis-associated hyperbilirubinemia in neonates, preventing neurological damage.
Area of Science:
- Neonatal Medicine
- Biochemistry
- Medical Diagnostics
Background:
- Elevated total/plasma bilirubin (TB) in neonates is primarily caused by increased bilirubin production due to hemolysis.
- Untreated neonatal hyperbilirubinemia increases the risk of bilirubin-induced neurological dysfunction (BIND).
- Carbon monoxide (CO) and bilirubin are equimolar products of heme catabolism.
Purpose of the Study:
- To review the biology of bilirubin production.
- To assess the clinical utility of a novel point-of-care end-tidal CO (ETCOc) device for identifying hemolysis in newborns.
- To introduce the application of ETCOc measurements in a neonatal cohort in China.
Main Methods:
- Review of the heme catabolic pathway and bilirubin production.
- Evaluation of a newly developed point-of-care ETCOc device.
- Analysis of ETCOc measurements in a cohort of neonates.
Main Results:
- End-tidal CO (ETCOc) measurements serve as a direct indicator of ongoing hemolysis.
- The novel point-of-care ETCOc device is effective in identifying hemolysis-associated hyperbilirubinemia in neonates.
- The study provides insights into the use of ETCOc in a Chinese neonatal population.
Conclusions:
- Accurate and timely identification of hemolysis is crucial for preventing neonatal hyperbilirubinemia and BIND.
- The ETCOc device offers a promising, non-invasive method for detecting hemolysis in newborns.
- ETCOc measurement represents a valuable tool for neonatal care and research.
Abstract:
The predominant cause of elevated total/plasma bilirubin (TB) levels is from an increase in bilirubin production primarily because of ongoing hemolysis. If undiagnosed or untreated, the risk for developing extreme neonatal hyperbilirubinemia and possibly bilirubin-induced neurological dysfunction (BIND) is increased. Since carbon monoxide (CO) and bilirubin are produced in equimolar amounts during the heme catabolic process, measurements of end-tidal CO levels, corrected for ambient CO (ETCOc) can be used as a direct indicator of ongoing hemolysis. A newly developed point-of-care ETCOc device has been shown to be a useful for identifying hemolysis-associated hyperbilirubinemia in newborns. This review summarizes the biology of bilirubin production, the clinical utility of a novel device to identify neonates undergoing hemolysis, and a brief introduction on the use of ETCOc measurements in a cohort of neonates in China.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Pancreatitis II: Collaborative Care
Assessment:

